by –News Direct–
Genetic Technologies Ltd (ASX:GTG; NASDAQ:GENE) CEO Simon Morriss tells Proactive the focus over the next 18 years is putting the pathway in place to see the business on track to profitability. GTG recently confirmed that its expanded geneType Multi-Risk Test, to include three new diseases – pancreatic cancer, melanoma and atrial fibrillation – is now available to order in Australia, following the launch of the expanded test in the US in March. The geneType Multi-Risk Test now performs a total of nine individual serious disease risk assessments, all from the one simple saliva sample and caters for people of most ethnicities over the age of 30.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/genetic-technologies-building-pathway-to-profitability-122093074
Genetic Technologies Ltd
COMTEX_441095200/2655/2023-09-27T15:40:04
Julian Lopez is professor emeritus of finance, served as the founding academic affairs dean and founding chair of the finance department.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No journalist was involved in the writing and production of this article.